Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting
May 16 2018 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led
biopharmaceutical company committed to identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in aesthetic and medical dermatology and immunology,
announced data of interest featured in posters at the International
Investigative Dermatology (IID) 2018 Meeting in Orlando,
Florida. Two posters relate to ESKATA™ (hydrogen peroxide)
topical solution, 40% (w/w), known formerly as “A-101”, and one
poster describes pre-clinical studies of soft Janus kinase 1/3
inhibitors synthesized by Aclaris and designed for high skin
permeability with minimal systemic stability.
- A-101 (hydrogen peroxide) topical solution Safety and Efficacy
in Patients with Seborrheic Keratoses: Results from two Identical
Randomized, Double-blind, Placebo-controlled, Phase 3 Studies
- Abstract 465
- Authors: L. Baumann, A. Blauvelt, Z. Draelos, S. Kempers, M.
Lupo, J. Schlessinger, S. Smith, D. Wilson, M. Bradshaw, E. Estes
and S.D. Shanler
- Study sponsored by Aclaris
- Ex-vivo Evaluation of Cytotoxicity and Melanocyte Viability of
Fitzpatrick V Skin after A-101 hydrogen peroxide topical solution
40% or Cryosurgery Treatment in Seborrheic Keratosis Lesions
- Abstract 1281, E-poster Discussion I, 5/17/18, 12:15 - 1:15
PM
- Authors: S. Kao, A. Kiss, T. Efimova, A. Friedman (Department
of Dermatology at The George Washington University School of
Medicine & Health Sciences)
- Supported by an independent grant from Aclaris
- JAK Kinase Inhibitors Efficacious in Models of Murine Contact
Hypersensitivity
- Abstract 1064
- Authors: P. Changelian, S. Mnich, C. Xu, S. Hockerman, D.
Anderson, J. Jacobsen and J. Monahan
- Authors are employees of Aclaris
The abstracts are available in the Journal of Investigative
Dermatology, Volume 138, Issue 5, Supplement, May 2018.
About ESKATA™ ESKATA (hydrogen peroxide)
topical solution, 40% (w/w), is the first and only FDA-approved
medication for the treatment of raised seborrheic keratoses (SKs).
Important Safety Information and Approved
Use
ESKATA can cause serious side effects,
including:
- Eye problems. Eye problems can
happen if ESKATATM (hydrogen peroxide) topical solution, 40%
(w/w) gets into your eyes, including: ulcers or small holes in your
eyes, scarring, redness, irritation, eyelid swelling, severe eye
pain, and permanent eye injury, including blindness.
- If ESKATA accidentally gets into your eyes, your
healthcare provider will tell you to flush them well with water for
15 to 30 minutes. Your healthcare provider may send you
to another healthcare provider if needed.
- Local skin reactions. Skin
reactions have happened in and around the treatment area after
application of ESKATA. Severe skin reactions can include: breakdown
of the outer layer of the skin (erosion), ulcers, blisters and
scarring. Tell your healthcare provider if you have any skin
reactions during treatment with ESKATA.
The most common side effects of ESKATA
include: itching, stinging, crusting, swelling,
redness and scaling.
Your healthcare provider will not apply another treatment of
ESKATA if your treated area is still irritated from the previous
treatment.
Tell your healthcare provider right away if ESKATA gets into
your eyes, mouth or nose during application. ESKATA is for
topical use on the skin only, and is not for use in your eyes,
mouth or vagina.
These are not all the possible side effects of ESKATA.
Approved Use for ESKATA
ESKATA is a prescription medicine used to treat seborrheic
keratoses that are raised.
ESKATA is for use as an in-office treatment. ESKATA is applied
by your healthcare provider and is not for use at home.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Contact Aclaris
Therapeutics, Inc. at 1-833-ACLARIS or 1-833-225-2747
or FDA at 1-800-FDA-1088
or www.fda.gov/medwatch.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company committed to identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in dermatology, both aesthetic and medical, and immunology.
Aclaris’ focus on market segments with no FDA-approved medications
or where treatment gaps exist has resulted in the first
FDA-approved treatment for raised seborrheic keratoses and several
clinical programs to develop medications for the potential
treatment of common warts, alopecia areata, androgenetic alopecia,
and vitiligo. For additional information, please visit
www.aclaristx.com and follow Aclaris on LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
"believe", "expect", "may", "plan," "potential," "will," and
similar expressions, and are based on Aclaris' current beliefs and
expectations. These forward-looking statements include expectations
regarding the commercial use of ESKATA and the pre-clinical and
clinical development of Aclaris JAK inhibitor compounds. These
statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such
statements. Risks and uncertainties that may cause actual results
to differ materially include uncertainties inherent in the conduct
of clinical trials, Aclaris' reliance on third parties over which
it may not always have full control, and other risks and
uncertainties that are described in the Risk Factors section of
Aclaris' Annual Report on Form 10-K filed for the year ended
December 31, 2017, Aclaris’ Quarterly Report on Form 10-Q filed
earlier for the quarter ended March 31, 2018 and other filings
Aclaris makes with the U.S. Securities and Exchange Commission from
time to time. These documents are available under the "Financial
Information" section of the Investors page of Aclaris' website at
http://www.aclaristx.com. Any forward-looking statements speak only
as of the date of this press release and are based on information
available to Aclaris as of the date of this release, and Aclaris
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Aclaris ContactMichael Tung, M.D.Senior Vice President Corporate
Strategy/Investor
Relations484-329-2140mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024